Biosimilar medicines: marketing authorisation
Submitted by Anonymous (not verified) on 24 February 2025 - 9:11
Biosimilar medicines: marketing authorisation
Orphan designation: human anti-promyostatin monoclonal antibody (apitegromab) Treatment of spinal muscular atrophy, 14/12/2018 Positive
Submitted by Anonymous (not verified) on 24 February 2025 - 9:10
Orphan designation: human anti-promyostatin monoclonal antibody (apitegromab) Treatment of spinal muscular atrophy, 14/12/2018 Positive
Orphan designation: Lomitapide Treatment of familial chylomicronaemia, 17/12/2010 Positive
Submitted by Anonymous (not verified) on 24 February 2025 - 8:50
Orphan designation: Lomitapide Treatment of familial chylomicronaemia, 17/12/2010 Positive
Kisqali
Submitted by Anonymous (not verified) on 24 February 2025 - 8:30
Kisqali
Infectious Diseases Working Party (IDWP) consolidated 3-year rolling work plan 2025-2027
Submitted by Anonymous (not verified) on 21 February 2025 - 14:20
Infectious Diseases Working Party (IDWP) consolidated 3-year rolling work plan 2025-2027
Infectious Diseases Working Party
Submitted by Anonymous (not verified) on 21 February 2025 - 14:20
Infectious Diseases Working Party
Consolidated 3-year rolling work plan for the Oncology Working Party : January 2025 - December 2027
Submitted by Anonymous (not verified) on 21 February 2025 - 14:15
Consolidated 3-year rolling work plan for the Oncology Working Party : January 2025 - December 2027
Oncology Working Party
Submitted by Anonymous (not verified) on 21 February 2025 - 14:15
Oncology Working Party
Funding
Submitted by Anonymous (not verified) on 21 February 2025 - 11:29
Funding
Agenda of the COMP meeting 3-5 December 2024
Submitted by Anonymous (not verified) on 21 February 2025 - 11:12
Agenda of the COMP meeting 3-5 December 2024